Quest Diagnostics (DGX) recently introduced its first consumer-initiated blood-draw test for PFAS (Per- and Polyfluorinated alkyl substances, also known as "forever chemicals") on questhealth.com. In contrast to traditional direct-to-consumer tests, the new test involves physician oversight and consultation on request with a licensed physician.The PFAS (Forever Chemicals) Test Panel is also widely available, with individuals having the option to visit most of DGX’s approximately 2,100 patient service center ...

The fourth-quarter reporting cycle is in full swing. The MedTech companies (Zacks-defined Medical Products stocks) within the broader Medical sector have witnessed a year-over-year deterioration in earnings.The MedTech stocks that have released their earnings so far showed market share gain within their base businesses through the months of the fourth quarter compared with the same period in 2022. However, ongoing macroeconomic headwinds in the form of inflation and labordemics put pressure on the bottom li ...

Based on technology from SkylineDx, the test aims to aid treatment decisions for patients with the deadliest form of skin cancer Patients classified as low-risk by MelaNodal Predict are shown to have survival rate of over 90 percent  SECAUCUS, N.J., and SAN DIEGO, Feb. 13, 2024 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the nation's leading provider of diagnostic information services, today announced the launch of MelaNodal Predict™, a highly advanced predictive gene expression test to help personalize ...

Directed at individuals who may be at risk of elevated PFAS exposure, the new test detects and measures PFAS identified by National Academies of Sciences, Engineering, and Medicine Organizations interested in workforce, community, and research population testing may also access the test SECAUCUS, N.J., Feb. 12, 2024 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leader in diagnostic information services, today announced the availability of the first consumer-initiated, physician-ordered blood- ...

AzmanJaka Investment Thesis Quest Diagnostics (NYSE:DGX) is an exceptionally stable company that operates a fantastic business. Over the last 10 years, its total return has exceeded that of the S&P500, and in the last 20 years, its shares have never fallen by more than 36%, even during the crises of 2008 and 2020. This fact underscores the resilience and strength of the business. However, in 2020, the company benefited from COVID-19 testing, which atypically boosted growth and margins, leading to an ove ...

Quest Diagnostics Inc. (NYSE:DGX) Q4 2023 Results Conference Call February 1, 2024 8:30 AM ET Company Participants Shawn Bevec - Vice President of Investor Relations Jim Davis - Chairman, Chief Executive Officer and President Sam Samad - Chief Financial Officer Conference Call Participants Patrick Donnelly - Citi Elizabeth Anderson - Evercore ISI Pito Chickering - Deutsche Bank. Jack Meehan - Nephron Research Brian Tanquilut - Jefferies Andrea Alfonso - UBS Lisa Gill - JPMorgan Derik de Bruin - Bank of Amer ...

For the quarter ended December 2023, Quest Diagnostics (DGX) reported revenue of $2.29 billion, down 1.9% over the same period last year. EPS came in at $2.15, compared to $1.98 in the year-ago quarter.The reported revenue represents a surprise of +1.80% over the Zacks Consensus Estimate of $2.25 billion. With the consensus EPS estimate being $2.14, the EPS surprise was +0.47%.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Str ...

Quest Diagnostics Incorporated’s (DGX) fourth-quarter 2023 adjusted earnings per share (EPS) of $2.15 beat the Zacks Consensus Estimate by 0.5%. The metric also surpassed the year-ago adjusted figure by 8.6%.Certain one-time expenses, like the ones related to amortization expenses, certain restructuring and integration charges, other expenses and excess tax benefits associated with stock-based compensations, were excluded from the quarter’s adjusted figures.GAAP earnings came in at $1.70 per share compared ...

Quest Diagnostics (DGX) came out with quarterly earnings of $2.15 per share, beating the Zacks Consensus Estimate of $2.14 per share. This compares to earnings of $1.98 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 0.47%. A quarter ago, it was expected that this medical laboratory operator would post earnings of $2.19 per share when it actually produced earnings of $2.22, delivering a surprise of 1.37%.Over the last four qua ...

SECAUCUS, N.J., Jan. 31, 2024 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the nation's leading provider of diagnostic information services, today announced that it has been selected as one of FORTUNE's World's Most Admired Companies in 2024 for the tenth consecutive year.  Fortune's World's Most Admired Companies recognition is based on nine criteria of corporate reputation, from innovation and quality of management and products, to social responsibility and people management. "I'm grateful to our dedica ...